The Emerging Roles of N6-Methyladenosine (m6A) Deregulation in Polycystic Ovary Syndrome
May 2025
in “
Journal of Ovarian Research
”
TLDR m6A deregulation plays a key role in PCOS and could lead to new treatments.
The document explores the role of N6-methyladenosine (m6A) deregulation in polycystic ovary syndrome (PCOS), emphasizing its impact on reproductive and metabolic processes. m6A modifications, involving proteins like METTL3 and FTO, are crucial in PCOS pathogenesis, affecting ovulation, endometrial receptivity, and chronic inflammation. The study highlights the potential of m6A-related proteins as biomarkers and therapeutic targets, with treatments like metformin, anti-androgens, and psychological therapy addressing various PCOS symptoms. The document also discusses the influence of gut flora on PCOS and the promise of therapies like Chinese herbs, probiotics, and phytochemicals in managing the condition. Further research is needed to develop targeted therapies for PCOS.